Prevest Denpro Ltd

- As per the call transcript, Atul Modi mentioned that at present, there is no capex plan because the company has already made a huge investment in the new project and R&D. - The company stated there is no immediate requirement for further capital expenditure. - Any future capex or fundraising needs will be evaluated and addressed as and when required. - No explicit mention of any current or upcoming fundraising through debt or equity was made during the call. - The focus remains on utilizing existing capacity and maintaining profitability without new debt or equity raising in the near term.

- Currently, there is no immediate capex plan as the company has already made significant investments in new projects and R&D. - The existing capacity is sufficient, with capability to increase production by adding shifts without new capital expenditures for several years. - Any future capital expenditure will be considered as needed, but no plans are in place at present. - The company is focusing on strategic investments in sales and marketing, digital marketing, e-commerce channels, new product portfolios, and increasing visibility through dental trade shows and associations. - Expansion plans include building a new facility to increase capacity, but this does not currently imply immediate capex beyond existing allocations.

- Prevest DenPro expects to double sales/revenue in the next 2-3 years due to established products and brand (Page 17). - The company aims to grow market share from 2% to around 12% in the medium term (Page 17). - Revenue growth guidance for next financial year is conservatively around 30%, with potential to exceed this (Page 7). - Growth will be supported by a stronger sales and marketing team focused on the domestic market (Page 17). - Expansion plans include increasing penetration in Indian markets by a few percentage points annually (Page 16). - Existing capacity can support doubling sales without immediate capex by adding shifts (Page 11). - New product launches (oral hygiene, biomaterials) with better-than-existing margins are expected to contribute to growth once regulatory approvals are obtained (Page 13). - Emphasis on digital marketing, e-commerce, and participation in dental trade shows to boost sales (Page 6).

- The company aims to double its sales in the next two to three years, leveraging established product quality and a strong market presence (Page 17). - Revenue growth target for the next financial year is conservatively estimated at 30%, with potential to perform better (Page 7). - EBITDA margins have been strong at around 39% in recent years, with expectations to maintain or improve these margins alongside growth (Page 7, Page 9). - Net profit increased by 36% in the last financial year, showing improved efficiency and effective cost management (Page 5). - Earnings per share (EPS) grew significantly, with FY22-23 EPS at INR 13.09, reflecting strong value creation for shareholders (Page 5). - Margin maintenance is a key focus while scaling; cost pressures related to increased sales and marketing are expected but margins will be preserved (Page 17).

- The transcript does not provide explicit details on the current or expected order book or pending orders for Prevest DenPro Limited. - However, it is mentioned that the company receives instant orders from foreign buyers, necessitating an increase in inventory to meet these demands (Page 12). - The company is also in talks with several MNCs for large manufacturing deals and plans to enter markets like Brazil, Russia, and the US (Page 14). - No specific figures or quantitative data on order books or pending orders were disclosed during the call. - Overall, the company anticipates faster growth in sales and market share, with new product lines ready for commercialization pending regulatory approvals, suggesting an optimistic order pipeline.